Видео ютуба по тегу Petauri Evidence

We are Petauri Evidence
We are Petauri Evidence
Petauri Evidence at ISPOR Annual 2025 - Montreal
Petauri Evidence at ISPOR Annual 2025 - Montreal
Navigating US payer evidence needs to optimise market access
Navigating US payer evidence needs to optimise market access
Introduction and Software Implementation of Non-Proportional Hazards in Network Meta-Analysis
Introduction and Software Implementation of Non-Proportional Hazards in Network Meta-Analysis
Which types of evidence are valued in the US market?
Which types of evidence are valued in the US market?
Antibiotic development landscape in the US and Europe - ISPOR Europe research poster
Antibiotic development landscape in the US and Europe - ISPOR Europe research poster
How can RWE address data gaps in health economic modelling for HTA?
How can RWE address data gaps in health economic modelling for HTA?
First to Market: Unlocking Switzerland’s Pharma Potential
First to Market: Unlocking Switzerland’s Pharma Potential
Highlights from ISPOR Europe 2024
Highlights from ISPOR Europe 2024
World EPA 2025
World EPA 2025
What Proportion of the Total Value Generated by New Drugs Accrues to Manufacturers?
What Proportion of the Total Value Generated by New Drugs Accrues to Manufacturers?
Global implications of the US's MFN pricing reforms
Global implications of the US's MFN pricing reforms
Use of QALYs in Decision-Making in Europe, Canada, and the US
Use of QALYs in Decision-Making in Europe, Canada, and the US
AI in systematic review: accuracy, efficiency and performance
AI in systematic review: accuracy, efficiency and performance
Communicating value to US Payers: Insights for Pharma and Medtech
Communicating value to US Payers: Insights for Pharma and Medtech
Breaking the pilot cycle in the NHS
Breaking the pilot cycle in the NHS
Pharma pricing: strategies for loss of exclusivity
Pharma pricing: strategies for loss of exclusivity
Global Pharma and Medtech market access and HEOR
Global Pharma and Medtech market access and HEOR
What is driving the increase in terminated NICE approvals? - ISPOR Europe research
What is driving the increase in terminated NICE approvals? - ISPOR Europe research